Sarcopenia and lean-mass preservation during weight reduction — evidence across compounds
Every compound the Institute assesses in sarcopenia and lean-mass preservation during weight reduction, with its certainty rating.
§2Evidence across compounds
Every compound the Institute assesses in this indication, with the effect as recorded, the certainty rating and the contributing trials. Effects are reported on the anchor outcome where the contributing trials measured it and on the outcome the trial actually reported where they did not.
Table 1. Compounds assessed in sarcopenia and lean-mass preservation during weight reduction, ordered by certainty.
| Compound | Effect as recorded | Interval as reported | Certainty | Trials |
|---|---|---|---|---|
| SemaglutideGLP-1 receptor agonist (acylated, long-acting) | Approximately 39 % of total mass lost was lean mass in the DXA substudy | substudy n = 140; not powered for a comparative conclusion | Low | 1 |
| TirzepatideDual GIP and GLP-1 receptor agonist (acylated) | Approximately 25 % of total mass lost was lean mass in the body-composition substudy | substudy n = 160 | Low | 1 |
| CJC-1295Growth-hormone-releasing hormone analogue with… | No randomised human evidence identified | — | Very low | 0 |
| GHRP-2Growth-hormone secretagogue, ghrelin receptor agonist… | No randomised human evidence identified for a body-composition outcome | — | Very low | 0 |
| IGF-1 LR3Recombinant insulin-like growth factor 1 analogue | No randomised human evidence identified for this analogue | — | Very low | 0 |
| IpamorelinGrowth-hormone secretagogue, selective ghrelin receptor… | No randomised human evidence identified | — | Very low | 0 |
| Estimates in this table are not on a common scale and must not be subtracted from one another. Where a comparison between two compounds has been made directly, it appears in a synthesis and not here. | ||||
§2.1Syntheses bearing on this indication
- Change in lean mass during pharmacologically induced weight reduction — Low
- Clinical evidence for growth-hormone secretagogues supplied for research — Very low
- Mitochondria-targeted peptides in bioenergetic disorders — Low
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183 · PMID 33567185
- Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet 2021;397(10278):971–984. doi:10.1016/S0140-6736(21)00213-0 · PMID 33667417
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.